Search
Lixudebart
go.drugbank.com/drugs/DB19244InvestigationalLixudebart, an investigational first-in-class monoclonal antibody, aims to reverse fibrosis.[L50833]
1D09C3
go.drugbank.com/drugs/DB05121ExperimentalThe antibody was isolated in collaboration with MorphoSys from its HuCAL(R) library of human antibodies. 1D09C3 binds to certain cell surface receptors, selectively killing activated, proliferating MHC … class II-positive tumor cells, which include those in B-cell and T-cell lymphomas. 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing
Zalutumumab
go.drugbank.com/drugs/DB12202InvestigationalZalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR).
Tarcocimab tedromer
go.drugbank.com/drugs/DB18937InvestigationalSevere to Severe Non-proliferative Diabetic Retinopathy (NPDR)). … Tarcocimab tedromer is under investigation in clinical trial NCT06270836 (A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately
GS-441524
go.drugbank.com/drugs/DB15686InvestigationalGS-441524 is an adenosine nucleotide analog antiviral, similar to [remdesivir].[A203057,L13239] This molecule was patented in 2009. … [A203057,A203057] GS-441524 continues to be studied in the treatment of Feline Infectious Peritonitis Virus, a coronavirus that only infects cats.[A198840]
Phenoperidine
go.drugbank.com/drugs/DB13605ExperimentalCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeMLN-977
go.drugbank.com/drugs/DB05431ExperimentalIt is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.
Verpasep caltespen
go.drugbank.com/drugs/DB04959InvestigationalHsp65, similar to other members of its family of proteins, elicits a strong immune response and may be used to design vaccines against a number of different cancers.
Ciluprevir
go.drugbank.com/drugs/DB05868InvestigationalThe compound, named BILN 2061, is an orally active inhibitor of the HCV NS3 protease and the first member of this new drug class to be tested in humans.